Warnyta Minnaard
If the practitioner doesn’t know where the primary tumor is located, they cannot offer a targeted treatment plan, and nor can they give the patient an estimate of their life expectancy.
Back to newsMore news
Hartwig and Ultima Expand Collaboration to Advance WGS in Oncology Care
Hartwig and Ultima strengthen collaboration on whole‑genome sequencing Hartwig Medical Foundation to adopt Ultima Genomics’ UG200 sequencing system to accelerate …
In the media: Rarity – Personalised cancer treatment – fact not fiction
Imagine a world in which each person’s cancer is treated with a personalised, targeted medical treatment regimen. A world in …
Whole genome sequencing is reliable, has added value, and can be embedded perfectly into everyday pathology diagnostics
Source: website Netherlands Cancer Institute With the rapidly expanding tableau of (increasingly tumor-agnostic) targeted therapies, genome-driven cancer care has become …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.